摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-Methoxypropoxy)-2-methylpropan

中文名称
——
中文别名
——
英文名称
2-(3-Methoxypropoxy)-2-methylpropan
英文别名
2-(3-Methoxypropoxy)-2-methylpropane
2-(3-Methoxypropoxy)-2-methylpropan化学式
CAS
——
化学式
C8H18O2
mdl
——
分子量
146.23
InChiKey
SPNYZIAJDUDUMR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    10
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • FACTOR XA INHIBITORS
    申请人:Zhu Bing-Yan
    公开号:US20090298806A1
    公开(公告)日:2009-12-03
    The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.
    本发明涉及由公式I表示的化合物及其药学上可接受的盐、溶剂化合物、水合物和前药,这些化合物是凝血因子Xa的抑制剂。本发明还涉及制备这些化合物所使用的中间体,含有这些化合物的药物组合物,预防或治疗一系列由不良血栓形成表征的疾病的方法,以及抑制血样的凝血的方法。
  • Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use
    申请人:SANKYO COMPANY LIMITED
    公开号:EP0763524A1
    公开(公告)日:1997-03-19
    Compounds of formula (I): wherein: R1 is alkyl; R2a, R2b, R2c and R2d are the same or different and each is hydrogen, optionally substituted alkyl or various other organic groups; R3 is alkyl; R4 is a group of formula (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX): wherein: A1 is a single bond, alkylene or alkenylene; A2 is or alkenylene; A3 is a single bond, alkyleneor alkenylene; R5a and R5b are the same or different and each is hydrogen, alkyl or various other groups; R6 is alkyl or phenyl; R7 is hydrogen or alkyl; R8 is alkyl or various other groups; and n is 0 or 1] and pharmaceutically acceptable salts thereof have valuable inhibitory activity against acyl-CoA: cholesterol acyl transferase.
    式(I)化合物: 其中R1 是烷基;R2a、R2b、R2c 和 R2d 相同或不同,各自是氢、任选取代的烷基或各种其它有机基团;R3 是烷基;R4 是式 (II)、(III)、(IV)、(V)、(VI)、(VII)、(VIII) 或 (IX) 的基团: 其中A1 是单键、亚烷基或烯基;A2 是或烯基;A3 是单键、亚烷基或烯基;R5a 和 R5b 相同或不同,且各自是氢、烷基或各种其它基团;R6 是烷基或苯基;R7 是氢或烷基;R8 是烷基或各种其它基团;以及 n 是 0 或 1]及其药学上可接受的盐类对酰基-CoA:胆固醇酰基转移酶具有宝贵的抑制活性。
  • KIRMSE, W.;JANSEN, U., CHEM. BER., 1985, 118, N 7, 2607-2625
    作者:KIRMSE, W.、JANSEN, U.
    DOI:——
    日期:——
  • PIPERIDINE-DIONE DERIVATIVES
    申请人:Genentech, Inc.
    公开号:US20170001990A1
    公开(公告)日:2017-01-05
    The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A 1 , A 2 , A 3 , A 4 , R 1 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein, compositions including the compounds and methods of using the compounds.
  • US5880147A
    申请人:——
    公开号:US5880147A
    公开(公告)日:1999-03-09
查看更多